Showing results (31-40 of 59) with videos related to
Sort By:
Pageof 6
Journal of Managed Care Pharmacy : JMCP|March 12, 2008
Disease-related and all-cause health care costs of elderly patients with goutEric Q Wu, Pankaj A Patel, Andrew P Yu, et al.Journal of the American Academy of Dermatology|March 12, 2010
The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trialAlan Menter, Matthias Augustin, James Signorovitch, et al.The Journal of Rheumatology|April 17, 2009
Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?Eric Q Wu, Pankaj A Patel, Reema R Mody, et al.Pharmacoeconomics|August 12, 2009
Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's diseaseAndrew P Yu, Scott Johnson, Si-Tien Wang, et al.Current Medical Research and Opinion|December 15, 2010
Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitusBhavik J Pandya, Morgan Bron, Therese McCall, et al.Journal of the American Academy of Dermatology|May 28, 2011
The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasisAlexa Boer Kimball, Andrew P Yu, James Signorovitch, et al.Journal of Medical Economics|June 18, 2011
Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalersAndrew P Yu, Annie Guérin, Diego Ponce de Leon, et al.Clinical Lymphoma, Myeloma & Leukemia|June 25, 2011
Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myelomaEric Q Wu, Arielle G Bensimon, Maryna Marynchenko, et al.Journal of the American Academy of Dermatology|October 12, 2010
Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trialKristian Reich, James Signorovitch, Karthik Ramakrishnan, et al.Journal of Medical Economics|October 1, 2010
Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective studyAndrew P Yu, Jipan Xie, Arielle Bensimon, et al.Pageof 6